Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan;76(1):195-201.
doi: 10.1016/j.jhep.2021.08.028. Epub 2021 Sep 9.

Rational HCC screening approaches for patients with NAFLD

Amit G Singal  1 , Hashem B El-Serag  2
Affiliations
Review

Rational HCC screening approaches for patients with NAFLD

Amit G Singal et al. J Hepatol. 2022 Jan.

Abstract

Non-alcoholic fatty liver disease (NAFLD) is associated with an increased risk of developing hepatocellular carcinoma (HCC), especially among those who have cirrhosis or advanced fibrosis, but 20-30% of cases of NAFLD-related HCC occur in the absence of advanced fibrosis. The prevalence of NAFLD-related HCC is increasing in most countries worldwide. There are few direct data to support or refute the efficacy or effectiveness of HCC surveillance in NAFLD or to guide its application. We use evidence on surveillance in other conditions and studies on the clinical course of patients with NAFLD to arrive at recommendations for rational approaches to HCC surveillance in this growing cohort of patients. We also outline gaps in research and practice, including opportunities to advance the field.

Keywords: biomarkers; cirrhosis; fatty liver; guidelines; liver cancer; metabolic dysfunction; surveillance.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest Amit Singal has served as a consultant or on advisory boards for Bayer, FujiFilm Wako Diagnostics, Exact Sciences, Roche, Glycotest, and GRAIL. Hashem El-Serag had grant funding from Gilead, Merck, Wako and Glycotest. Please refer to the accompanying ICMJE disclosure forms for further details.

References

    1. Moon AM, Singal AG, Tapper EB. Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. Clin Gastroenterol Hepatol 2020;18:2650–2666. - PMC - PubMed
    1. McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of Hepatocellular Carcinoma. Hepatology 2020. - PMC - PubMed
    1. El-Serag HB, Kanwal F, Feng Z, Marrero JA, Khaderi S, Singal AG, Texas Hepatocellular Carcinoma C. Risk Factors for Cirrhosis in Contemporary Hepatology Practices-Findings From the Texas Hepatocellular Carcinoma Consortium Cohort. Gastroenterology 2020;159:376–377. - PMC - PubMed
    1. Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2021;18:223–238. - PMC - PubMed
    1. Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2018;68:723–750. - PubMed

Publication types

MeSH terms